sotagliflozin + ramipril

sotagliflozin + ramipril is an oral combination regimen consisting of sotagliflozin, a dual inhibitor of sodium-glucose cotransporter 2 (SGLT2) and sodium-glucose cotransporter 1 (SGLT1), and ramipril, an angiotensin-converting enzyme (ACE) inhibitor. Sotagliflozin lowers blood glucose and sodium reabsorption in the kidneys and the intestines, providing metabolic and potential cardiovascular benefits. Ramipril inhibits the conversion of angiotensin I to angiotensin II, reducing blood pressure and exerting cardioprotective effects. This combination is sometimes used in clinical practice for patients with type 2 diabetes and hypertension, but it is not currently available as a fixed-dose combination product, and no evidence suggests this regimen is marketed as a unique, branded product. The use together can be inferred based on clinical trials in which patients received both drugs in the context of managing diabetes and blood pressure[3][5].